



ASX ANNOUNCEMENT

Lumos receives largest FebriDx® order to-date

MELBOURNE, Australia (1 April 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has received its largest purchase order to-date from PHASE Scientific (“PHASE”).

Following the US FDA’s 510(k) PHASE clearance with CLIA waiver for FebriDx® on 27 March 2026, which unlocks a US\$1.0+ billion market opportunity and represents a 15x expansion of the addressable market for FebriDx®¹, Lumos’ US exclusive distributor, PHASE has lodged a purchase order valued at US\$1.3 million. This represents Lumos’ largest order for FebriDx to-date.

Commenting on the announcement, Doug Ward, CEO of Lumos Diagnostics said: *“Receiving our largest order to-date, so soon after the granting of CLIA waiver is a strong validation of the commercial opportunity for FebriDx® in the US market. We look forward to supporting PHASE as it scales its commercial rollout and drives adoption of FebriDx® across the much broader pool of urgent and primary care settings.”*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

References

1. Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database). Precision Business Insights, US Acute Respiratory Infections, 2024.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Tom Trezona – Australia
H^CK Acting Managing Director
tom@hck.digital
+61 411 235 692

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598